Ajit Singh, PhD, Former CEO of Siemens Oncology & Siemens Imaging Systems

Dr. Singh's Topics include:

• Future of Healthcare
• Healthcare Innovation - Beyond EMRs
• Technology & Innovation
• Artificial Intelligence in Healthcare
• Medical Devices
• Diagnostics
• AI in Life Sciences
• Oncology
• Innovation and Entrepreneurship
• Venture Capital

Ajit Singh is a Partner at Silicon Valley based Artiman Ventures, focused on early-stage technology and life science investments, with $1.2 Billion in assets under management. He serves on the boards of Sofie Biosciences – a PET radiopharmaceuticals company focused on Oncology and Neurology, Leo Cancer Care – focused on radiation oncology, Artidis – a cancer diagnostics company with nanomechanical biomarkers for disease, Harbinger Health – a Flagship Pioneering company, and CORE Diagnostics, a CAP-accredited molecular diagnostics laboratory. He also serves on the Board of Trustees of American Association for Cancer Research (AACR) Foundation, the oldest and the largest cancer research organization globally. Ajit is an Adjunct Professor in the School of Medicine at Stanford where he teaches clinical technologies and entrepreneurship.

In the past, Ajit has served as a Lead Director on the Board of Directors of Max Healthcare from 2009 to 2020 (Current Market Cap = USD 11 Billion) and as a Senior Advisor to the Tata Trusts Healthcare program – which developed a “plan centrally, deliver locally” platform and implemented it via comprehensive cancer centers built bespoke with funding from the Tata Group. Until recently, he also served on the board of directors of Cadila Pharmaceuticals. He was also the Executive Chairman of Summer Bio that performed 20 million PCR-based Covid tests during the two years of the pandemic – by creating a fully robotics-based lab from the ground up, with the shortest turnaround time (< 4 hours) and the lowest price (= $10) across the entire Covid-testing industry.

Prior to joining Artiman, Ajit was the President and CEO of Biolmagene, a digital pathology company with AI-based oncology diagnostics, based in Sunnyvale, California. Biolmagene was acquired by Roche in September 2010. Before Biolmagene, Ajit spent nearly twenty years at Siemens in various roles, in the US, and in Germany, most recently as the CEO of Siemens Oncology, and Siemens Digital Imaging Systems with global P&L responsibility and toplines of $500M and $1B respectively. Before transitioning to these executive responsibilities, Ajit spent several years in R&D at Siemens Research in Princeton, responsible for research in the areas of artificial intelligence and robotics. During this time, he concurrently served as an adjunct faculty at Princeton University.

Ajit has a Ph.D. in Computer Science from Columbia University, a master’s in computer engineering from Syracuse University, and a bachelor’s in electrical engineering from Indian Institute of Technology (IIT) in Varanasi, India. He has published two books and several refereed articles and holds five patents. His Top-10 Book Review is carried by various blogs and reading journals in December every year.

The Real Chemistry Podcast: Enhancing Healthcare Consistency Through AI: Ajit Singh, Artiman Ventures